Zu den Inhalten springen

Tumorzentrum Freiburg - CCCF

Prof. Dr. med. Justus Duyster

Contact:

Department for Internal Medicine I
University of Freiburg
Hugstetter Straße 55
79106 Freiburg
Telefon + 49 (0) 7 61 / 270 - 34 06 0
Telefax + 49 (0) 7 61 / 270 - 32 06 0
direktion-med1@uniklinik-freiburg.de
http://www.uniklinik-freiburg.de/medizin1.html

Current Positions:

Medical Director Internal Medicine I
Medical Director CCCF – Comprehensive Cancer Center Freiburg
Member executive committee DKTK

Research Focus:

  • Leukaemogenesis
  • GIST (gastrointestinal stromal tumor)
  • Personalized therapy based on molecular and genetic examinations, individual targeted therapies

Clinical Focus:   

  • Acute myeloid Leukemia (AML) and acute lymphatic leukemia (ALL)
  • Chronic myeloproliferative diseases: chronic myeloid leukemia (CML), polycythemic vera (PV), idiopathic myelofibrosis (IMF) as well as essential thrombozythemia (ET)
  • GIST (gastrointestinal stromal tumor)
  • Molecular therapy,  antibody based tumor therapies, therapeutic use of kinase inhibitors

DKTK Reseach Topics:

Joint Funding project: Evaluation of new therapeutic concepts in relapsed AML
Research Program Molecularly Targeted Therapies
Topic: Targeting Transcription and Epigenetics

Working Group Members DKTK:

PD Dr. Reinhard Marks    
Dr. Christoph Cornelius Miething        
Dr. Anna-Lena Illert
Dr. Petya Apostolova

Publications DKTK:

Dechow T, Steidle S, Götze KS, Rudelius M, Behnke K, Pechloff K, u. a. GP130 activation induces myeloma and collaborates with MYC. Journal of Clinical Investigation. 1. Dezember 2014;124(12):5263–74.

Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, u. a. BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia. Journal of Clinical Investigation [Internet]. 20. Oktober 2014 [zitiert 21. Oktober 2014]; Verfügbar unter: http://www.jci.org/articles/view/76539

Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R. MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. Leukemia [Internet]. 26. Mai 2017 [zitiert 7. Juni 2017]; Verfügbar unter: http://www.nature.com/doifinder/10.1038/leu.2017.137

Reinhardt H, Trittler R, Eggleton AG, Wöhrl S, Epting T, Buck M, Kaiser S, Jonas D, Duyster J, Jung M, Hug MJ, Engelhardt M. Paving the Way for Dose Banding of Chemotherapy: An Analytical Approach. J Natl Compr Canc Netw. April 2017;15(4):484–93. 

Andrlová H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, Wernet F, Follo M, Technau-Hafsi K, Has C, Rao Mittapalli V, Idzko M, Herr R, Brummer T, Ungefroren H, Busch H, Boerries M, Narr A, Ihorst G, Vennin C, Schmitt-Graeff A, Minguet S, Timpson P, Duyster J, Meiss F, Römer W, Zeiser R. Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression. Oncotarget [Internet]. 17. April 2017 [zitiert 7. Juni 2017]; Verfügbar unter: http://www.oncotarget.com/abstract/17160

Müller TA, Grundler R, Istvanffy R, Rudelius M, Hennighausen L, Illert AL, Duyster J. Lineage specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3+-mediated leukemic phenotype. Leukemia [Internet]. 5. April 2016 [zitiert 11. April 2016]; Verfügbar unter: http://www.nature.com/doifinder/10.1038/leu.2016.72 

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na I-K, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. Oktober 2015;29(10):2062–8. 

Gorantla SP, Zirlik K, Reiter A, Yu C, Illert AL, Von Bubnoff N, Duyster J. F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC - a novel mode of kinase inhibitor resistance. Leukemia [Internet]. 12. März 2015 [zitiert 18. März 2015]; Verfügbar unter: http://www.nature.com/doifinder/10.1038/leu.2015.70

Site Coordinator Freiburg

Prof.Dr. Christoph Peters
Tumorzentrum Freiburg CCCF
Phone: +49-761-270-71500
Hugstetter Str. 55
79106 Freiburg

and

Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Str. 17
79104 Freiburg
Phone: +49-761-203-9600/9601
christoph.peters@mol-med.uni-freiburg.de​​    

Administrative Site Coordination

Dr. Anja Hernández
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
+49 (0)761 270 22810
anja.hernandez@dkfz-heidelberg.de